Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update
May 8, 2018 4:01 PM EDTTargeting DEXTENZA NDA Resubmission in the Second Quarter of 2018
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2018 and provided a business update.
We entered 2018 with an exciting set of opportunities that include a number of regulatory and clinical milestones, said Antony Mattessich, President and Chief Executive Officer. With the right strategy, objectives and leadership in... More
